The effects of octreotide on healing of small bowel anastomosis

Samuel K. Miller, Robert Martindale, Xiao X. Gao, Thomas R. Gadacz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Octreotide (OCT) is a somatostatin analog used for its inhibitory action on multiple GI functions. Although octreotide has numerous clinical benefits, it has also been shown to inhibit postresectional hyperplasia of small bowel and hepatic regeneration. Because octreotide inhibits both trophic and anabolic hormones, we hypothesize that the use of octreotide may be detrimental in patients with a recent bowel anastomosis. To test this hypothesis, 60 male rats were randomized to four equal groups following small bowel anastomosis. Group I = control; Group II = 10 mg/day of hydrocortisone succinate; Group III = 2.5 μg/kg/day octreotide (equivalent of a clinical dose); Group IV = 25 μg/kg/day octreotide. Hydrocortisone was used as a negative control because it is known to have inhibitory effects on small bowel anastomotic healing. On postoperative Day 7, bursting pressures were measured. Serum T-kininogen levels, as a marker for systemic inflammation, and hydroxyproline content from the anastomotic segments were obtained. These results indicate that in the rat small bowel model, octreotide did not have any deleterious effect on anastomotic strength, systemic inflammation, and collagen content, even at high doses. Hydrocortisone, as expected, showed significant detrimental effects on bursting strength, as well as decreasing systemic inflammation. These findings have significant clinical implications, as octreotide could be used without jeopardizing the intestinal anastomosis.

Original languageEnglish (US)
Pages (from-to)733-737
Number of pages5
JournalAmerican Surgeon
Volume62
Issue number9
StatePublished - 1996
Externally publishedYes

Fingerprint

Octreotide
Inflammation
Hydrocortisone
Kininogens
Hydroxyproline
Somatostatin
Hyperplasia
Regeneration
Collagen
Hormones
Pressure
Control Groups
Liver
Serum

ASJC Scopus subject areas

  • Surgery

Cite this

Miller, S. K., Martindale, R., Gao, X. X., & Gadacz, T. R. (1996). The effects of octreotide on healing of small bowel anastomosis. American Surgeon, 62(9), 733-737.

The effects of octreotide on healing of small bowel anastomosis. / Miller, Samuel K.; Martindale, Robert; Gao, Xiao X.; Gadacz, Thomas R.

In: American Surgeon, Vol. 62, No. 9, 1996, p. 733-737.

Research output: Contribution to journalArticle

Miller, SK, Martindale, R, Gao, XX & Gadacz, TR 1996, 'The effects of octreotide on healing of small bowel anastomosis', American Surgeon, vol. 62, no. 9, pp. 733-737.
Miller, Samuel K. ; Martindale, Robert ; Gao, Xiao X. ; Gadacz, Thomas R. / The effects of octreotide on healing of small bowel anastomosis. In: American Surgeon. 1996 ; Vol. 62, No. 9. pp. 733-737.
@article{16d9aa2a84a24d07b0b4d2d2dc5d1951,
title = "The effects of octreotide on healing of small bowel anastomosis",
abstract = "Octreotide (OCT) is a somatostatin analog used for its inhibitory action on multiple GI functions. Although octreotide has numerous clinical benefits, it has also been shown to inhibit postresectional hyperplasia of small bowel and hepatic regeneration. Because octreotide inhibits both trophic and anabolic hormones, we hypothesize that the use of octreotide may be detrimental in patients with a recent bowel anastomosis. To test this hypothesis, 60 male rats were randomized to four equal groups following small bowel anastomosis. Group I = control; Group II = 10 mg/day of hydrocortisone succinate; Group III = 2.5 μg/kg/day octreotide (equivalent of a clinical dose); Group IV = 25 μg/kg/day octreotide. Hydrocortisone was used as a negative control because it is known to have inhibitory effects on small bowel anastomotic healing. On postoperative Day 7, bursting pressures were measured. Serum T-kininogen levels, as a marker for systemic inflammation, and hydroxyproline content from the anastomotic segments were obtained. These results indicate that in the rat small bowel model, octreotide did not have any deleterious effect on anastomotic strength, systemic inflammation, and collagen content, even at high doses. Hydrocortisone, as expected, showed significant detrimental effects on bursting strength, as well as decreasing systemic inflammation. These findings have significant clinical implications, as octreotide could be used without jeopardizing the intestinal anastomosis.",
author = "Miller, {Samuel K.} and Robert Martindale and Gao, {Xiao X.} and Gadacz, {Thomas R.}",
year = "1996",
language = "English (US)",
volume = "62",
pages = "733--737",
journal = "The American surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "9",

}

TY - JOUR

T1 - The effects of octreotide on healing of small bowel anastomosis

AU - Miller, Samuel K.

AU - Martindale, Robert

AU - Gao, Xiao X.

AU - Gadacz, Thomas R.

PY - 1996

Y1 - 1996

N2 - Octreotide (OCT) is a somatostatin analog used for its inhibitory action on multiple GI functions. Although octreotide has numerous clinical benefits, it has also been shown to inhibit postresectional hyperplasia of small bowel and hepatic regeneration. Because octreotide inhibits both trophic and anabolic hormones, we hypothesize that the use of octreotide may be detrimental in patients with a recent bowel anastomosis. To test this hypothesis, 60 male rats were randomized to four equal groups following small bowel anastomosis. Group I = control; Group II = 10 mg/day of hydrocortisone succinate; Group III = 2.5 μg/kg/day octreotide (equivalent of a clinical dose); Group IV = 25 μg/kg/day octreotide. Hydrocortisone was used as a negative control because it is known to have inhibitory effects on small bowel anastomotic healing. On postoperative Day 7, bursting pressures were measured. Serum T-kininogen levels, as a marker for systemic inflammation, and hydroxyproline content from the anastomotic segments were obtained. These results indicate that in the rat small bowel model, octreotide did not have any deleterious effect on anastomotic strength, systemic inflammation, and collagen content, even at high doses. Hydrocortisone, as expected, showed significant detrimental effects on bursting strength, as well as decreasing systemic inflammation. These findings have significant clinical implications, as octreotide could be used without jeopardizing the intestinal anastomosis.

AB - Octreotide (OCT) is a somatostatin analog used for its inhibitory action on multiple GI functions. Although octreotide has numerous clinical benefits, it has also been shown to inhibit postresectional hyperplasia of small bowel and hepatic regeneration. Because octreotide inhibits both trophic and anabolic hormones, we hypothesize that the use of octreotide may be detrimental in patients with a recent bowel anastomosis. To test this hypothesis, 60 male rats were randomized to four equal groups following small bowel anastomosis. Group I = control; Group II = 10 mg/day of hydrocortisone succinate; Group III = 2.5 μg/kg/day octreotide (equivalent of a clinical dose); Group IV = 25 μg/kg/day octreotide. Hydrocortisone was used as a negative control because it is known to have inhibitory effects on small bowel anastomotic healing. On postoperative Day 7, bursting pressures were measured. Serum T-kininogen levels, as a marker for systemic inflammation, and hydroxyproline content from the anastomotic segments were obtained. These results indicate that in the rat small bowel model, octreotide did not have any deleterious effect on anastomotic strength, systemic inflammation, and collagen content, even at high doses. Hydrocortisone, as expected, showed significant detrimental effects on bursting strength, as well as decreasing systemic inflammation. These findings have significant clinical implications, as octreotide could be used without jeopardizing the intestinal anastomosis.

UR - http://www.scopus.com/inward/record.url?scp=0029761770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029761770&partnerID=8YFLogxK

M3 - Article

C2 - 8751764

AN - SCOPUS:0029761770

VL - 62

SP - 733

EP - 737

JO - The American surgeon

JF - The American surgeon

SN - 0003-1348

IS - 9

ER -